Thermostable Vaccines and Thermostable Biologics Market

According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85% this is believed to prevent close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. However, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distribution and shipping). In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. For some vaccines, even the slightest variations in temperature / storage conditions can adversely alter product integrity and / or viability. Over time, technological advancements in the methods of biologics development and manufacturing have prompted the developers to explore the potential of thermostable vaccines and thermostable biologics. Thermostable vaccines can be stored at room temperature for prolonged period of time, thereby eliminating the need for cold chain requirements in storage and transportation. This enables reduction in costs incurred during storage and transportation and, subsequently, the overall costs involved in mass immunization projects. In addition, it allows the suppliers to deliver the products in safe and convenient manner even to far-flung destinations.

Leave a Reply